How can we help?
$60.00
The COVID-19 pandemic wreaked havoc on the U.S. economy and the drug testing industry. All the hot issues were affected, including testing for marijuana, switching to oral fluid testing, and telehealth collections. Learn about all these issues and more while hearing the results of the survey. Many companies use the survey’s results to help them formulate important sales and marketing strategies.
Bill Current, President Current Consulting Group
Member price: $50
$60 for non-members
After purchase, you will receive access to a link that allows you to download the video file for this recorded session. The link expires after 60 days.
Search this site
Stay in touch
Give to NDASA
Invest in safe and drug-free communities and workplaces and support NDASA.
Latest News & Updates
- Sep 26, 2022New Drug Testing Technologies and State Drug Testing Laws
- Sep 12, 2022Need That Test Result Yesterday!
- Aug 05, 2022Make Your Voices Heard! Comment on Proposed Amendment to DOT Record-Keeping Regulations
- Jun 08, 2022Where Are We and Where Are We Going? The State of Drug Testing and the Future
- Jun 07, 2022NDASA Responds to SAMHSA Proposed Rules for Oral Fluid Testing in Federal Workplaces
Topics We Track
- Advocacy (3)
- Business Development (1)
- Committee Reports (1)
- DOT (6)
- Drug & Alcohol Testing (22)
- Drug Legislation (8)
- Feature (53)
- FMCSA (3)
- For Drug Testing Industry Professionals (14)
- For Employers and Workplace Safety & Wellness Professionals (12)
- Industry News (11)
- Marijuana & CBD (13)
- Member Benefits (1)
- Membership (3)
- NDASA Conference (10)
- NDASA Guidance (4)
- Opioids (2)
- Resources (21)
- Substance Use (1)
- Substance Use/Addiction (3)
- Training (1)
- Uncategorized (7)
- Workplace Safety (4)